development of its best-in-class and first-in-class immuno-oncology programs STRASBOURG, France & MONTREAL- Domain Therapeutics , a biopharmaceutical company specializing in the research and development of innovative

March 2022 " Explicyte grants Domain Therapeutics exclusivity on data related to GPCR implicated in Strasbourg and Bordeaux, France, March 10, 2022 – Domain Therapeutics , a biopharmaceutical company specializing their expertise to identify GPCR targets and associated biomarkers to discover and develop breakthrough therapeutic

April 2022 Ono Enters into Collaboration Agreement with Domain Therapeutics and Université de Montréal and CEO: Gyo Sagara ; “Ono”) today announced that it has newly signed a collaboration agreement with Domain Therapeutics S.A. (Strasbourg, France; CEO: Pascal Neuville ; “Domain”) and Université de Montréal (Québec, Canada; “UdM

This gap is due to their unique autoproteolytic cleavage in the GAIN domain, creating a heterodimer of technology for high-throughput screening of pharmacological compound libraries to identify potential therapeutic Therapeutics North America Inc, Montréal, Québec, Canada (2) Department of Pharmacology-Physiology, Laurent Sabbagh on the web Domain Therapeutics Characterizing hADGRE5/CD97 Activation and Signaling: Domain Therapeutics North America Inc., Montreal, Quebec, Canada 3.

of GPCRs in disease states to help test the feasibility of using protein-targeted degradation as a therapeutic GPCR Previous Event Next Event Great Lakes GPCR Retreat and Club des Récepteurs à Sept Domaines Transmembranaires du Québec Great Lakes GPCR Retreat and Club des Récepteurs à Sept Domaines Transmembranaires du Québec

We hope our research will aid in the development of new therapeutic interventions for the alleviation GPCR Previous Event Next Event Great Lakes GPCR Retreat and Club des Récepteurs à Sept Domaines Transmembranaires du Québec Great Lakes GPCR Retreat and Club des Récepteurs à Sept Domaines Transmembranaires du Québec